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Objectives. This study examined the modification of recombi- 
nant tissue-type plasminogen activator (rt-PA)-induced throm- 
bolysis by recombinant lys-plasminogen. 
Background. Recombinant issue-type plasminogen activator 
restores flow in the thrombosed coronary artery, but the artery 
often reocclndes. The rt-PA-induced thrombolysis is a result of 
activation of plasminogen bound to fibrin in the thrombus and 
results in generation of the fibrinolytic enzyme plasmin. Small 
amounts of lys-plasminogen are formed when rt-PA is used. 
Lys-plasminogen binds to fibrin with a 10-fold greater affinity 
than the predominant native glu-plasminogen, leading to a loose 
fibrin structure. 
Methods. Dogs with electrically induced occlusive intracoro- 
nary thrombus were treated with saline solution (n --- 9), glu- 
plasminogen (2 mg/kg body weight, n = 5) or lys-plasmiuogen 
(2 mg/kg, n = 5), followed by infusion of rt-PA (1 mg/kg over 
20 min) 10 rain later. 
Results. Reperfusion rates were similar in all groups of dogs, 
but the time to reflow was lowest in dogs given lys-plasminogen 
compared with those given saline solution or glu-plasminogen 
before rt-PA (mean [+SE] 14 -+ 2 vs. 22 -+ 2 and 23 -+ 3 rain, 
respectively, p < 0.05). None of the reperfused coronary arteries 
reoccluded in the lys-plasminogen plus rt-PA group, whereas 
75% reoccluded in dogs given saline solution plus rt-PA, and 50% 
reoccluded in those given glu-plasminogen plus rt-PA. Accord- 
ingly, duration of reflow was greater in the lys-plasminogen plus 
rt-PA group (>120 vs. 39 -+ 7 and 82 -+ 21 min, respectively, p < 
0.05). Plasminogen activator inhibitor-1 activity decreased uring 
rt-PA infusion and thereafter increased in all dogs, but less so in 
dogs given lys-plasminogen (p < 0.05 vs. those given saline 
solution before rt-PA). 
Conclusions. Treatment with recombinant lys-plasminogen be- 
fore rt-PA reduces time to reflow and sustains reflow after 
thrombolysis, whereas glu-plasminogen has no such effect. 
(J Am Coll Cardiol 1995;25:753-60) 
Recombinant tissue-type plasminogen activator (rt-PA) is an 
efficient activator of the fibrinolytic system (1,2) and is fre- 
quently used in patients with acute myocardial infarction to 
achieve thrombolysis. The patency of the coronary arteries 
after t-PA treatment is on the order of 60% to 80%. However, 
20% to 30% of coronary arteries reocclude after establishment 
of flow (3-5). In animal models of coronary artery thrombosis 
as well, rt-PA is often used to dissolve the occlusive thrombus 
and to study the comparative efficacy of different thrombolytic 
regimens (6-11). The thrombolytic efficacy of rt-PA depends 
on its dose and the rapidity of administration. I  addition, the 
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plasma level of rt-PA after infusion determines whether the 
coronary artery will stay open or reocclude. Because the 
half-life of rt-PA in dog plasma is -5  rain (8), the plasma levels 
of rt-PA decline soon after the infusion is discontinued, 
facilitating coronary artery reocclusion. Availability of clot- 
bound plasminogen is essential for the activity of rt-PA. 
Accordingly, it has also been suggested (12-14) that local 
depletion of plasminogen atthe site of thrombus may relate to 
the limited thrombolytic efficacy and short-lasting effects of 
various fibrinolytic agents. 
All presently available thrombolytic agents convert plasmin- 
ogen to plasmin, which rapidly breaks down fibrin, resulting in 
thrombolysis. Plasma contains 0.2 to 0.3 g/liter of plasminogen 
with glutamic acid as its amino terminal, which is generally 
referred to as glu-plasminogen (15). On exposure to plasmin, 
the amino-terminal region of glu-plasminogen (fragment Glu 1 
to Lys77 ) is cleaved off, and lys-plasminogen (atruncated form 
of the native form of plasminogen) is formed (16). Lys- 
plasminogen binds to fibrin with a 10-fold greater affinity than 
glu-plasminogen (17), and the affinity increases when fibrin is 
initially degraded by plasmin (18). Binding of lys-plasminogen 
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to fibrin affects the fibrin clot structure (15) and results in the 
formation of more easily soluble clots (19). 
Incorporation ofplasminogen i to the streptokinase mole- 
cule results in improved binding to the fibrin in the clot 
compared with streptokinase alone, which leads to more 
efficient fibrinolysis, as is evident from a duration of action four 
times longer, and duration of administration is reduced by 50% 
(20). The thrombolytic efficacy of uroldnase is also enhanced 
by previous administration of lys-plasminogen i  dogs with 
thrombosis of the femoral artery (21,22). Similar results were 
obtained with the combination oflys-plasminogen a d one- or 
two-chain urokinase or rt-PA in in vitro (23). 
In the present study, we examined the hypothesis that 
administration f lys-plasminogen before rt-PA would enhance 
the thrombolytic effect of rt-PA compared with saline solution 
or glu-plasminogen administered before rt-PA. Our study, 
conducted in dogs with electrically induced intracoronary 
thrombus, shows that administration of lys-plasminogen i - 
deed enhances the thrombolytic efficacy of rt-PA. 
Methods  
Coronary artery thrombosis. Nineteen mongrel dogs of 
either gender weighing a mean of 21 kg (range 18 to 25) were 
anesthetized with pentobarbital sodium (30 mg/kg body 
weight), intubated and placed on positive-pressure v ntilation 
with a respirator (Harvard Apparatus). A left thoracotomy was 
performed in the fifth intercostal space, and the heart was 
suspended in a pericardial cradle. The left anterior descending 
coronary artery was isolated istal to the first diagonal branch. 
An ultrasound Doppler flow probe (Crystal Biotech) was 
placed in the left anterior descending coronary artery for 
monitoring coronary blood flow. An intracoronary thrombus 
was induced by using the technique initially described by 
Romson et al. (10) and subsequently used by us (6-9) and 
others (11). In brief, the left anterior descending coronary 
artery was gently rubbed to disrupt he endothelium distal to 
the flow probe, and a silver-coated copper wire with a 25-gauge 
needle tip (-4 ram) bent 90 ° was inserted istal to the flow 
probe into the left anterior descending coronary artery and 
pulled back to ensure contact with the intimal surface of the 
vessel. This electrode was connected in series with a 250,000- 
ohm variable resistor to the anode (positive terminal) of a 9-V 
nickel-cadmium battery. The cathode (negative terminal) was 
secured to subcutaneous ti sues. In all dogs, the left anterior 
descending coronary artery was narrowed by a pneumatic 
occluder placed istal to the flow probe and the electrode. The 
degree of occlusion was designed to reduce peak reactive 
hyperemia fter a 10-s period of total occlusion by at least 
50%. The thrombus formation was initiated with passage of 
direct current (100 ~A) through the intracoronary electrode 
until left anterior descending coronary flow was zero for at 
least 30 min with the electric urrent urned off and the plastic 
occluder removed. 
In the core of left anterior descending coronary artery- 
supplied myocardium, myocardial segmental shortening was 
measured by placement of ultrasound crystals in the mid- 
myocardium. The orientation of the crystals, separated by 1.0 
to 1.5 cm, lay transverse to the long ventricular axis and was 
aligned so that the optimal acoustic signal was obtained (24). 
End-diastolic segmental length (EDL) and end-systolic seg- 
mental length (ESL) were measured at aortic valve opening 
and closing, respectively, as determined from the high fidelity 
aortic root pressure waveform (25). Regional myocardial seg- 
mental function was determined as [(EDL - ESL)BEDL] x 
100%. Catheters were inserted into both femoral veins and 
advanced into the inferior vena cava and used for both drug 
infusion and collection of blood samples. 
Hemodynamic measurements. In addition to continuous 
measurement of coronary blood flow, ascending aortic pres- 
sure was measured by inserting a catheter-tipped pressure 
transducer (Millar) into the carotid artery and advancing it to 
the aortic root. Heart rate was calculated from the pressure 
waveform. The recordings were made on a Honeywell mul- 
tichannel recorder. 
Administration of saline solution, glu- and lys-plasminogen 
and rt.PA. After the in situ intracoronary thrombus was 
stable, as indicated by zero blood flow with the electric urrent 
on, the pneumatic occluder was released and the current 
abruptly turned off. The dogs were then observed for 20 rain 
and the stability of thrombus confirmed. Thereafter, the ani- 
mals were given saline solution (n = 9), glu-plasminogen 
(2 mg/kg, body weight n -- 5) or lys-plasminogen (2 mg/kg, n = 
5) by the intravenous route over a 2-min period. Ten minutes 
later all dogs were given rt-PA (1 mg/kg) over a 20-min period 
by a Harvard perfusion pump, and they were observed for 2 h 
for evidence of coronary artery reperfusion and reocclusion. 
Blood flow characteristics were also observed with special 
attention to development of cyclic flow changes. 
Plasma plasminogen activator inhibitor-1 activity and plas- 
minogen levels. Samples of peripheral venous blood were 
collected in sterile disposable plastic syringes (Becton- 
Dickinson) before creation of the thrombus, during the period 
of stable occlusive thrombus and at multiple times during and 
after administration f rt-PA. All samples were transferred to
polypropylene tubes containing sodium citrate (0.13 tool/liter) 
and aprotinin (0.3 mg/ml) and immediately placed on ice. 
Blood samples were centrifuged at 1,500 g for 15 min, and 
plasma samples were stored at -70°C for measurement of 
plasminogen activator inhibitor-1 (PAl-l) activity and plasmin- 
ogen levels, which were completed within 4 weeks of blood 
collection. 
The PAI-1 activity levels were measured as previously 
described (7,8). Plasma plasminogen levels were assayed by a 
standard enzyme-linked immunosorbent assay (ELISA) using 
a monoclonal ntibody against human plasminogen asa catch- 
ing antibody and a polyclonal antibody raised in rabbits against 
plasminogen as a detecting antibody. The antibody had no 
cross-reactivity with dog plasminogen. 
Agents. Recombinant lys- and glu-plasminogen were ob- 
tained from Health Care Group of Novo Nordisk, Gentofte, 
Denmark. Lys-plasminogen was produced in baby hamster 
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Table 1. Thrombolytic Effects of Saline Solution and Glu- and Lys-Plasminogen Given 10 min Before 
Recombinant Tissue-Type Plasminogen Activator 
Saline Glu- Lys- 
Solution Plasminogen Plasminogen 
(n = 9) (n = 5) (n = 5) 
Prethrombus CBF (ml/min) 
Time to zero flow (rain) 
Reperfusion rate 
Time to restored coronary flow (min) 
Peak restored coronary flow (ml/min) 
CBF at end of observation (ml/min) 
Duration of reperfusion (min) 
Reocclusion rate 
30_+3 31_+4 34_+4 
34_*7 37-+4 37-+3 
8/9 (88) 4/5 (80) 5/5 (100) 
22 -+ 3 23 _+ 3 14 _+ 2* 
51 _+ 8 63 _+ 17 73 -+ 10' 
8-+4 18+7 34_+5* 
39 _+ 7 82 + 21 >120' 
6/8 (75) 2/4 (50) 0/5 (0)* 
*p < 0.05 versus dogs given saline solution or glu-plasminogen before recombinant tissue-type lasminogen activator 
(rt-PA). An occlusive intracoronary thrombus was induced in all dogs. After 20 min of stable thrombus, the dogs were 
given saline solution or glu- or lys-plasminogen over 2 min. Ten minutes later, all dogs received rt-PA (1 mg/kg) over 
20 min. Data presented are mean value - SEM or number (%) of dogs. CBF = coronary blood flow. 
kidney cells (26), and the protein was purified by cation 
exchange and by affinity chromatography on a lysine sepharose 
column (Pharmacia, Uppsala, Sweden). Human glu-plasminogen 
was prepared from human plasma and purified on a lysine 
sepharose column. The purification procedures were essentially 
those described previously by Deutsch and Mertz (27). Both 
preparations were freeze-dried, supplied in vials containing lu- 
or lys-plasminogen (25 mg) and dissolved in 10 ml of isotonic 
saline solution just before use. The rt-PA was produced with 
recombinant technology by Genentech and was supplied in vials 
containing 50 mg of rt-PA. 
Statistical analysis. Data were analyzed with regard to the 
maximal coronary blood flow as well as its duration after 
reperfusion. Time to thrombus formation, time to infusion of 
thrombolytic agent and time to restoration ofblood flow were 
also analyzed. Frequency of thrombolysis and reocclusion rates 
in the three groups of dogs were compared using the Fisher 
exact est. Effect of different regimens on plasma plasminogen 
levels and PAI-1 activity were compared by one-factor re- 
peated measures analysis of variance followed by the Scheff6 F
test (Statview, Abacus Concepts) using a Macintosh Ilcx 
computer. All data are expressed as mean value _+ SEM. 
Resu l ts  
Thrombolytic effects of saline solution and glu- and lys- 
plasminogen given before rt-PA. The comparative thrombo- 
lytic effects of the three regimens are shown in Table 1. Left 
anterior descending coronary artery blood flow in the three 
groups of dogs before thrombus formation was similar (30 _+ 
3 ml/min for the saline solution plus rt-PA group; 
31 +_ 4 ml/min for the glu-plasminogen plus rt-PA group; 34 _ 
4 ml/min in the lys-plasminogen plus rt-PA group). Mean time 
to thrombus formation was also similar in the three groups of 
dogs. There was no evidence of spontaneous reflow in any of 
the dogs during the 20-rain period of clot stabilization or the 
subsequent 10-rain period of observation before administra- 
tion of rt-PA, indicating that saline solution and glu- or 
lys-plasminogen did not have any direct hrombolytic effect. 
Reperfusion occurred in eight of nine dogs in the saline 
solution plus rt-PA group (reperfusion rate 88%). Mean time 
to occurrence of blood flow was 22 _+ 3 min. The restored flow 
was maintained for the 120-min period of observation i  only 
two of eight dogs with initial thrombolysis (reocclusion rate 
75%). The peak restored flow in the eight dogs with reperfu- 
sion was 51 ___ 8 ml/min. At 60 min of reperfusion, the 
magnitude ofcoronary flow was 8 -+ 4 ml/min. Results from a 
representative experiment are shown in Figure 1. 
Reperfusion occurred in four of five dogs in the glu- 
plasminogen plus rt-PA group (reperfusion rate 80%). Time to 
reflow was 23 _+ 3 rain, and peak restored flow was 63 --- 
17 ml/min (both p = NS vs. saline solution plus rt-PA). The 
flow persisted for 2 h in two dogs, 112 min in one dog and 
60 rain in the remaining dog with initial thrombolysis, resulting 
in a 50% reocclusion rate within 2 h. In the two dogs with 
evidence of reflow at 2 h, blood flow revealed frequent cyclic 
flow changes and periodic reocclusion. At 60 rain of reperfu- 
sion, the magnitude of restored coronary flow was 18 ___ 
7 ml/min (p = NS vs. saline solution plus rt-PA) in these dogs. 
A representative example of restored blood flow in a dog 
treated with glu-plasminogen followed by rt-PA is shown in 
Figure 2. 
Reperfusion occurred in all five dogs in the lys-plasminogen 
plus rt-PA group (reperfusion rate 100%). Time to reflow was 
14 +_ 2 min, and mean peak restored flow was 73 _+ 10 ml/min 
(both p < 0.05 vs saline solution or glu-plasminogen plus 
rt-PA). The flow persisted for 2 h in all five dogs and resulted 
in a 0% reocclusion rate at 2 h (p < 0.02 vs. the reocclusion 
rates in dogs given saline solution or glu-plasminogen before 
rt-PA). At 60 min of reperfusion, the magnitude of restored 
coronary flow was 34 _ 5 ml/min in these dogs (p = 0.02 vs. 
dogs given saline solution or glu-plasminogen before rt-PA). A 
representative example of restored blood flow in a dog treated 
with lys-plasminogen followed by rt-PA is shown in Figure 3. 
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Figure 1. Representative experiment showing induction 
of an occlusive intracoronary thrombus by delivery of 
anodal direct current (De). Administration f recombi- 
nant issue-type lasminogen activator ( t-PA) after saline 
solution causes a short-lasting restoration of coronary 
blood flow. Note the presence ofcyclic flow variations. 
Note the absence of cyclic flow variations, suggesting stable 
thrombolysis. 
Effects on myocardial function and systemic hemodynamic 
variables. Complete occlusion of the left anterior descending 
coronary artery in all dogs resulted in change in end-diastolic 
and end-systolic segmental length. The myocardial segmental 
dysfunction i dicated by paradoxic left ventricular contraction 
occurred in all dogs. At the end of the observation period, the 
shortening fractions were -5.3 _+ 2.6%, 0.5 _+ 1.1 and 1.0 _+ 
0% in dogs given saline solution or, glu- or lys-plasminogen, 
respectively, before rt-PA (p = NS) (Table 2). 
Neither saline solution nor glu-plasminogen, or lys- 
plasminogen had any effect on aortic pressure or heart rate. 
When the administration of these agents was followed by 
administration f rt-PA, there was only a modest effect on 
systemic hemodynamic variables. However, the effects were 
similar in all three groups of dogs (Table 2). 
Plasma plasminogen activator inhibitor-I activity. Plas- 
minogen activator inhibitor-1 (PAl-l) activity decreased dur- 
ing rt-PA infusion, indicating consumption fPAl-1 in all clogs 
(Fig. 4). However, in dogs given saline solution before rt-PA, 
PAI-1 levels began to increase at 20 rain after eperfusion and 
were not different from the control value at 120 min. In 
contrast, PAI-1 activity was suppressed in dogs given glu- or 
lys-plasminogen before rt-PA throughout the period of obser- 
vation (p < 0.05 vs. saline solution plus rt-PA). 
Plasma plasminogen levels. As expected, plasminogen lev- 
els in plasma increased in dogs given glu- or lys-plasminogen 
(Fig. 5). The increase in plasminogen levels was similar in lys- 
and glu-plasminogen-treated dogs. 
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Figure 2. Representative experiment showing the effect of 
glu-plasminogen administered 10 rain before recombinant 
tissue-type lasminogen activator ( t-PA). Although flow 
is sustained for the 2-h period of observation i  this 
experiment, coronary blood flow shows periodic yclic 
flow reductions and a brief period of intervening coronary 
artery reocclusion. DC = direct current. 
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Figure 3. Representative experiment showing the ef- 
fect of lys-plasminogen administered 10 rain before 
recombinant tissue-type lasminogen activator ( t- 
PA). The restored flow is sustained for the entire 2-h 
period of observation i  this experiment. Note the 
absence ofcyclic flow variations. DC = direct current. 
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Discussion 
Modification of rt-PA-induced thrombolysis by lys- 
plasminogen. The present study shows that administration f 
lys-plasminogen before rt-PA facilitates the thrombolytic effi- 
cacy of rt-PA in dogs with occlusive coronary artery thrombus, 
as is evident from the significantly shorter time to restoration 
of blood flow. The magnitude of restored flow was enhanced 
and coronary artery patency sustained for the entire 120 min of 
observation in all dogs given lys-plasminogen. I  addition, 
coronary flow restored by this regimen showed few cyclic flow 
variations. Coronary flow at the end of the observation period 
returned to the original level measured before induction of 
thrombus. The stable phasic coronary flow pattern (Fig. 3) 
seems to confirm that adequate hrombolysis was achieved and 
resulted in sustained patency at 120 min. Whereas, rt-PA plus 
saline solution restored blood flow in 8 of 9 dogs, coronary flow 
at the end of the observation period was only -25% of the 
original flow. Peak restored coronary flow was also significantly 
lower in dogs given saline solution plus rt-PA compared with 
those given lys-plasminogen before rt-PA. Notably, the admin- 
istration of glu-plasminogen before rt-PA did not significantly 
improve the thrombolytic potential of rt-PA. These observa- 
tions suggest that lys-plasminogen removes or diminishes the 
nidus for activation of the coagulation cascade, resulting in 
fibrin precipitation. Any remaining fibrin or partially degraded 
fibrin with exposure of thrombin receptors may form such a 
nidus (28). Notably, there was no significant effect of lys- 
plasminogen o  regional left ventricular function, which prob- 
ably reflects myocardial injury caused by prolonged ischemia. 
Lys- and glu-plasminogen and fibrinolysis. Limited plas- 
mic digestion of the native glu-plasminogen leads to formation 
of a truncated plasminogen with amino-terminal lysine, valine 
or methionine r sidues, which have been collectively referred 
to as lys-plasminogen. Small amounts of lys-plasminogen are 
generated during thrombolytic therapy (12,29), whereas under 
normal conditions extremely small amounts of this form 
of plasminogen are present in the plasma (30,31). Lys- 
plasminogen is more reactive than glu-plasminogen when 
40.  
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s 
Figure 4. Plasma levels of plasminogen activator inhibitor-1 ~ 25- 
(PAl-l) activity and plasminogen in the three groups of dogs. ~20- 
Note the rapid recovery ofPAl-1 activity in dogs treated with 
saline solution followed by recombinant tissue-type lasmino- ~ 15- 
gen activator ( t-PA). In contrast, the increase inPAI-1 activity 
during the late phase of observation is significantly less in dogs ~ lO- 
given glu-plasminogen (Glu-plg) or lys-plasminogen (Lyp-plg) ~ 5- 
before rt-PA. [ 
O- 
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Table 2. Systemic and Myocardial Effects of Saline Solution and Glu- and Lys-Plasminogen Given 10 min Before Recombinant Tissue-Type 
Plasminogen Activator 
Heart Rate (beats/rain) Mean Aortic Pressure (ram Hg) Shortening Fraction (%) 
Treatment During During During During During During During During During 
Before rt-PA Thrombus Occlusion Reperfusion Thrombus Occlusion Reperfusion Thrombus Occlusion Reperfusion 
Saline solution 162 _+ 8 162 _+ 10 169 _+ 10 118 - 7 111 _+ 8 102 -+ 8 9.3 - 1.5 -4.8 -+ 2.6 -5.3 - 2.6 
(n = 9) 
Glu-plasminogen 144 _+ 6 172 _+ 14 164 _+ 11 119 - 8 95 _+ 9 91 _+ 6 12.0 -+ 0.9 0 -+ 1.2 0.5 _+ 1.1 
(n = 5) 
Lys-plasminogen 144 _+ 4 154 _+ 5 156 _+ 8 129 _+ 5 112 _+ 8 115 _+ 2 12.5 -+ 0.5 0 -+ 0 1.0 _+ 0 
(n = 5) 
Data presented are mean value + SEM. rt-PA = recombinant tissue-type lasminogen activator. 
given with plasminogen activators, such as streptokinase, 
urokinase, prourokinase and rt-PA (32). It also binds to the 
specific sites on the fibrin molecule xposed after the proteol- 
ysis of fibrin (33). Compared with glu-plasminogen, lys- 
plasminogen has a more open structure, is more easily con- 
verted to plasmin and has greater absorption to clot-bound 
fibrin (30,31). These characteristics of lys-plasminogen may 
influence thrombolytic efficacy, when given with rt-PA or other 
thrombolytic agents and may explain the salutary effects ob- 
served in these experiments. 
However, administration of glu-plasminogen did not have 
the same beneficial effect as lys-plasminogen o rt-PA-induced 
thrombolysis. Glu-plasminogen binds to fibrin to a much lesser 
extent than lys-plasminogen (33,34). Some of the exogenous 
glu-plasminogen might have become bound to the fibrin in the 
thrombus that may have contributed to the unstable reocclu- 
sion observed in dogs given glu-plasminogen. The restoration 
of blood flow obtained with the addition of lys-plasminogen, 
but not glu-plasminogen, may well be explained by the en- 
hanced binding of lys-plasminogen to the thrombus, which 
facilitated formation of plasmin on the remaining fibrin. 
The thrombolytic effects observed in this study support he 
work by Badylak et al. (21,22), who demonstrated enhance- 
ment of the thrombolytic efficacy of urokinase by previous 
administration of lys-plasminogen i  a canine model of femo- 
ral artery thrombosis. The data on the thrombolytic potential 
of the combination of lys-plasminogen a d rt-PA presented in 
the present report suggest at least a twofold to threefold 
enhancement of the efficacy of rt-PA in the canine coronary 
thrombosis model. 
Coronary thrombosis and rt-PA-induced thrombolysis in 
the canine model. The model of coronary artery thrombosis in 
dogs used in the present study has been utilized by several 
investigators (6-11) to study the elficacy of agents that prevent 
or delay intravascular thrombosis, induce thrombolysis or 
prevent coronary artery reocclusion. The thrombus formed in 
the coronary artery on delivery of anodal direct current is a 
fibrin-platelet-rich clot because platelet as well as thrombin 
inhibitors delays the formation of the occlusive thrombus (11). 
The intimal surface of the coronary artery often reveals 
extensive ndothelial disruption (35). These features, along 
with the external narrowing of the coronary artery designed to 
mimic atherosclerotic narrowing, make this thrombus imilar 
to that seen in humans with acute myocardial ischemia (3). 
When given intravenously, rt-PA predictably induces 
thrombolysis n 60% to 90% of dogs with occlusive intracoro- 
nary thrombus, and the frequency of thrombolysis depends on 
the amount of rt-PA administered and the rapidity and dura- 
tion of administration of rt-PA (3,4). The dose-dependent 
thrombolytic effect of rt-PA is also evident in humans with 
acute myocardial infarction (4). The coronary artery often 
reoccludes in both dogs and humans soon after infusion of 
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Figure 5. The plasminogen levels increase and are sus- 
tained in dogs given glu- or lys-plasminogen before 
recombinant tissue-type plasminogen activator (rt-PA). 
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rt-PA is discontinued (3,5,36-38). The coronary reocclusion 
rate is frequently decreased by platelet inhibitors, such as 
thromboxane Az/endoperoxide r ceptor antagonists and glyco- 
protein IIb/IIIa receptor antibody, as well as by thrombin 
inhibitors, such as heparin, hirudin and argotroban (6,8,37- 
40), indicating involvement of the entire coagulation cascade, 
including platelets in coronary artery reocclusion after initial 
flow restoration. 
Platelet activation, rt-PA-induced thrombolysis and effect 
of plasminogens. The restored coronary flow with rt-PA is 
often associated with cyclic flow variations (3,4,34). The cyclic 
flow variations in the narrowed canine coronary artery have 
been attributed to platelet accumulation and are abolished by 
administration of platelet inhibitors (41). Even though rt-PA 
decreases platelet aggregation i a dose-dependent manner in 
vitro (42), it is not surprising that intracoronary platelet 
aggregation occurs as the plasma rt-PA concentrations decline. 
Dogs given saline solution or glu-plasminogen before rt-PA 
also continued to show cyclic flow changes (Fig. 2). In contrast, 
dogs given lys-plasminogen before rt-PA did not show cyclic 
flow variations. These potentially beneficial phenomena may 
be explained by sustained fibrinolytic activity at the site of the 
thrombus. Our recent in vitro studies suggest hat previous 
incubation of platelets with lys-plasminogen potentiates rt-PA- 
induced inhibition of platelet aggregation by at least one order 
of magnitude; however, glu-plasminogen has only a modest 
effect on rt-PA-induced platelet aggregation i hibition (43). A 
modest breakdown of fibrinogen with resultant increase in 
fibrinogen degradation products may also influence the occur- 
rence of cyclic flow changes and maintenance of blood flow 
because many fibrinogen degradation products exert coronary 
vasodilator and platelet inhibitory effects (44,45). The coronary 
flow-enhancing effects of these fibrin(ogen) degradation prod- 
ucts may also relate to the greater magnitude of restored flow 
in dogs given lys-plasminogen before rt-PA. 
Plasma rt-PA, PAI-1 and plasminogen levels. In associa- 
tion with the improved thrombolytic efficacy of rt-PA by 
previous administration of lys-plasminogen, plasma PAI-1 
activity was diminished, indicating suppression of the activity 
of this procoagulant factor. In a previous tudy (5) with K2P, a 
mutant of rt-PA with a half-life seven times longer than rt-PA, 
we observed a similar degree of sustained reflow and similar 
suppression of PAI-1 activity (5). As expected, plasminogen 
levels increased in dogs given lys- or glu-plasminogen. Al- 
though bleeding time or other indexes of active bleeding were 
not measured, we did not observe any significant excess 
bleeding from the chest cavity in dogs given lys-plasminogen 
compared with those given saline solution. Nonetheless, this 
aspect needs to be evaluated in subsequent s udies. 
Summary. We described potentiation of the thrombolytic 
effects of rt-PA with previous administration of lys- 
plasminogen i a dog model of intracoronary thrombus, prob- 
ably a result of potent binding of lys-plasminogen to clot- 
bound fibrin. The sustained reflow may result in improved 
myocardial function. By contrast, administration of the native 
form of plasminogen, glu-plasminogen, before rt-PA does not 
result in similar potentiation of the effects of rt-PA. 
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